We have located links that may give you full text access.
Comparative Study
Journal Article
Comparison between Open and Endovascular Repair for the Treatment of Juxtarenal Abdominal Aortic Aneurysms: A Single-Center Experience with Midterm Results.
Annals of Vascular Surgery 2017 May
BACKGROUND: To evaluate the optimal treatment for juxtarenal abdominal aortic aneurysm (JAAA), we compared the outcomes of open surgical repair (OSR) with endovascular aortic repair (EVAR) using a variety of fenestrated and snorkel EVARs.
METHODS: We evaluated overall survival, aneurysm-related death, reintervention, and renal impairment in 152 JAAAs retrospectively, excluding cases of aortic dissection and rupture. Cox models were used to assess survival and assessed postoperative dialysis rates following surgery.
RESULTS: OSR and EVAR were performed in 81 and 71 patients, respectively. The mean age was significantly higher in the EVAR group (overall, 74.5 years; OSR, 71 years; and EVAR; 77 years). High preoperative serum creatinine levels, cerebrovascular disease, and chronic obstructive pulmonary disease were more prevalent in the EVAR group. Mean operative time, hospital stay, and perioperative blood loss were significantly greater in the OSR group (P < 0.001 for all). The overall 30-day mortality was 1.9% with no statistical difference between 2 groups. The reintervention rate was significantly higher in the EVAR group (P = 0.01). Overall survival rates at 1, 3, 5, and 7 years were 97.4%, 91.6%, 86.3%, and 82.9%, respectively, with no significant difference between groups. Mortality in EVAR was associated with over 3.0 mg/dL of postoperative creatinine, and postoperative dialysis following OSR was associated with operative time and volume of bleeding.
CONCLUSIONS: Acceptable outcomes were observed with OSR and EVAR. However, reintervention was more frequently required following EVAR. OSR appears to be the most appropriate first-line treatment for JAAA in good-risk patients; however, EVAR may represent an alternative option in high-risk patients.
METHODS: We evaluated overall survival, aneurysm-related death, reintervention, and renal impairment in 152 JAAAs retrospectively, excluding cases of aortic dissection and rupture. Cox models were used to assess survival and assessed postoperative dialysis rates following surgery.
RESULTS: OSR and EVAR were performed in 81 and 71 patients, respectively. The mean age was significantly higher in the EVAR group (overall, 74.5 years; OSR, 71 years; and EVAR; 77 years). High preoperative serum creatinine levels, cerebrovascular disease, and chronic obstructive pulmonary disease were more prevalent in the EVAR group. Mean operative time, hospital stay, and perioperative blood loss were significantly greater in the OSR group (P < 0.001 for all). The overall 30-day mortality was 1.9% with no statistical difference between 2 groups. The reintervention rate was significantly higher in the EVAR group (P = 0.01). Overall survival rates at 1, 3, 5, and 7 years were 97.4%, 91.6%, 86.3%, and 82.9%, respectively, with no significant difference between groups. Mortality in EVAR was associated with over 3.0 mg/dL of postoperative creatinine, and postoperative dialysis following OSR was associated with operative time and volume of bleeding.
CONCLUSIONS: Acceptable outcomes were observed with OSR and EVAR. However, reintervention was more frequently required following EVAR. OSR appears to be the most appropriate first-line treatment for JAAA in good-risk patients; however, EVAR may represent an alternative option in high-risk patients.
Full text links
Related Resources
Trending Papers
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.European Journal of Neurology 2024 May 17
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app